Potential neutralizing antibodies discovered for novel corona virus using machine learning

Rishikesh Magar1, Prakarsh Yadav2, Amir Barati Farimani3,4,5

  • 1Department of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.

Scientific Reports
|March 5, 2021
PubMed

Insights

Machine learning models identified nine stable synthetic antibodies capable of inhibiting SARS-CoV-2. This high-throughput approach accelerates the discovery of neutralizing antibodies to combat viral threats like COVID-19.

Area of Science:

  • Immunology
  • Computational Biology
  • Virology

Background:

  • Rapid virus mutations, like those in SARS-CoV-2, pose significant threats due to delayed immune responses.
  • Developing effective neutralizing antibodies is crucial for controlling viral outbreaks and saving lives.

Purpose of the Study:

  • To develop a high-throughput method for predicting neutralizing antibodies against SARS-CoV-2.
  • To identify stable, synthetic antibody sequences with potential inhibitory effects on the virus.

Main Methods:

  • Utilized machine learning (ML) models, including XGBoost, Random Forest, Multilayered Perceptron, Support Vector Machine, and Logistic Regression.
  • Employed graph featurization on a dataset of 1933 virus-antibody sequences and clinical neutralization response data.
  • Integrated bioinformatics, structural biology, and Molecular Dynamics (MD) simulations for candidate antibody validation.

Main Results:

  • Screened thousands of hypothetical antibody sequences using various ML methods.
  • Identified nine stable antibody sequences demonstrating potential to inhibit SARS-CoV-2.
  • Validated the stability and inhibitory potential of candidate antibodies through multi-disciplinary approaches.

Conclusions:

  • Machine learning offers a powerful tool for high-throughput prediction of neutralizing antibodies.
  • The identified synthetic antibodies represent promising candidates for therapeutic development against SARS-CoV-2.
  • Combining computational prediction with experimental validation accelerates the discovery of antiviral therapies.